New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 12, 2014
08:01 EDTHALOHalozyme upgraded to Buy from Neutral at UBS
UBS transitioned coverage on Halozyme with a Buy rating from a Neutral rating. The firm upgraded shares due to valuation and is more bullish on the PEGPH20 program following the recently removed clinical hold and believes the Herceptin-SC launch is tracking well and provides near-term support and strong uptake. Price target raised to $16 from $%14.
News For HALO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
16:41 EDTHALOHalozyme sees 2015 revenue $85M-$95M, consensus $97.69M
Subscribe for More Information
16:41 EDTHALOHalozyme reports Q4 EPS (4c), consensus (7c)
Reports Q4 revenue $30.4M, consensus $25.59M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use